Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)

NCT07099742 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing the effectiveness and safety of the drug tirzepatide in adults with obesity, with or without type 2 diabetes.

Status Not yet recruiting Approved but enrollment has not started.

Type Observational

Participants 364 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-09 · est. completion 2026-07

Where 3 sites · Bangladesh

What this study is testing ClinicalTrials.gov NCT07099742 ↗

Description as written by the study sponsor.

This is a prospective, multicenter, real-world study conducted in Bangladesh to assess the effectiveness and safety of Tirzepatide compared to structured lifestyle interventions, including dietary modifications and exercise, in obese adults with or without Type 2 Diabetes Mellitus (T2DM). The study aims to determine whether treatment with Tirzepatide results in superior weight reduction outcomes compared to lifestyle-based approaches. Adult participants (≥18 years) with a body mass index (BMI) ≥25 kg/m² and no prior exposure to GLP-1 receptor agonists will be enrolled at the discretion of the treating physician. Eligible participants will receive either once-weekly Tirzepatide or participate in lifestyle intervention programs aligned with standard clinical care.

Treatments tested

Tirzepatide Drug

Exposure
Life Style Modification Behavioral

Referent group - Lifestyle interventions, exercise, and diet control

Main thing measured	Percentage change in body weight at Week 24 in both treatment groups.
Sponsor	Dr. Md. Alimur Reza
Conditions studied	Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07099742 ↗